Marapharm Ventures (CSE:MDM) has announced that steps are underway to create a cannabis campus with facilities on its property.
Linda Sampson, CEO of Marapharm, said:

Future plans could include a research and development laboratory, cultivation, ancillary products and processing. One existing building is presently being used for a tier 3 cannabis cultivator, licensed for up to 30,000 square feet of cultivation space. Currently, there are operations in only a 1500 square foot section of the building, while the remainder of the building is being prepared to undergo extensive renovations. The smaller space includes room for mothers, clones, vegetation, cultivation, drying, curing and processing, and also allows the license holder to produce approximately $50,000 US per harvest and 4 harvests have been produced since September 2016. This smaller space has enabled them to generate revenue in order to partially pay lease payments while training staff and developing specific strains to bring to market. The harvests are pre-sold to dispensaries and retailers are patiently waiting for the new strains and products that will be produced in the completed 30,000 square foot facility. Construction can finally get underway, because we now own the property and we anticipate the renovations to be completed on or before May 30, 2017. Once construction is complete in the main area, the remainder of the building will undergo the same upgrades.
The license holder also has an unlimited square footage processing license. Marapharm has a 9.000 square foot building alongside the cultivation center to be used as a processing facility. Applications for permits and regulatory approvals are underway. The facility will have Vitalis CO2 extraction equipment, a packaging center and a kitchen for edibles. The extraction equipment is designed to extract oil while maintaining the valuable terpene profile of each strain, and has a 90L capacity. The double chambers allow the equipment to operate without a down time during processing cycles. A menu of pre-approved edibles will be produced in the fully-equipped industrial kitchen. This turnkey designed facility will be a signature and highly functional space and is projected to produce revenues for the license holders of more than $2 million each month.

Click here to read the full press release.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less


  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info:

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less